Free Trial

Vertex Pharmaceuticals Prepares for Key Kidney Drug Decision as Pipeline Readouts Loom

Vertex Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Vertex is on track for the FDA’s Nov. 30 decision on povetacicept for IgA nephropathy and says it is prepared to launch if approved. Late-stage data showed a greater than 50% reduction in proteinuria at 36 weeks; the company also cited serious infection rates of 0.5% in both the treatment and placebo groups.
  • Several pipeline milestones lie ahead: interim phase 3 data for kidney drug inaxaplin are expected in Q1 2027, while phase 3 diabetic-neuropathy results for JOURNAVX are expected in the first half of 2027. Vertex also expects proof-of-concept data for a myotonic dystrophy treatment before year-end.
  • Vertex expects JOURNAVX and CASGEVY to contribute more than $500 million toward annual revenue guidance of over $13 billion. JOURNAVX prescriptions for acute pain are projected to more than triple in 2026 versus 2025, though reimbursement and prescription logistics have slowed revenue conversion.
  • MarketBeat previews top five stocks to own in December.

Vertex Pharmaceuticals NASDAQ: VRTX is preparing for a Nov. 30 U.S. regulatory decision on its kidney disease treatment povetacicept, while awaiting clinical results across kidney disease, chronic pain and other conditions, company executives said at a UBS investor event.

Susie Lisa, Vertex’s senior vice president of investor relations, said the company remains “fully on track” for the Food and Drug Administration’s decision on povetacicept for immunoglobulin A nephropathy, or IgAN. The company is ready to launch the treatment if it is approved, she said.

Lisa also reaffirmed Vertex’s expectation that JOURNAVX and CASGEVY, its products outside cystic fibrosis, will contribute more than $500 million toward the company’s annual revenue guidance of more than $13 billion. She said third-quarter cystic fibrosis growth was balanced between the U.S. and international markets.

Vertex Prepares for Kidney Drug Decision

Asked about investor concerns surrounding a contract manufacturer supporting povetacicept, Lisa did not discuss inspection or review specifics. She said the events expected during the FDA’s priority review had taken place and that Vertex had held positive interactions with the agency.

Lisa said povetacicept’s late-stage results included a greater than 50% reduction in proteinuria, or protein in the urine, at 36 weeks. She described the drug as a potential best-in-class treatment, while noting that there have been no head-to-head studies against competing products. The treatment is designed for monthly administration at home using an auto-injector.

Some investors have questioned whether reductions in immunoglobulin G, an antibody, could lead to safety concerns or additional monitoring requirements. Lisa said serious infection rates were 0.5% in both the povetacicept and placebo arms of the study. Vertex expects a label consistent with competing treatments, she said, while cautioning that monitoring differed across trials.

Two competing IgAN drugs have already launched, but Lisa said Vertex sees a substantial remaining opportunity. She estimated that 160,000 patients in the U.S. have a biopsy-confirmed IgAN diagnosis. More than 90% of Vertex’s trained renal sales force has prior nephrology experience, she said, and the company has held discussions with payers.

Inaxaplin Data and Genetic Testing

Vertex expects an interim analysis in the first quarter of 2027 from AMPLITUDE, a phase 3 study of inaxaplin for APOL1-mediated kidney disease, or AMKD. A positive result could put the drug on a path toward accelerated approval in the U.S., Lisa said.

The analysis will assess the slope of estimated glomerular filtration rate, a measure of kidney function, at 48 weeks. Lisa said earlier studies showed encouraging reductions in proteinuria, but distinguished that measure from the kidney-function endpoint being assessed for regulatory purposes.

Lisa estimated that the initial U.S. patient population could be about 150,000, rising to roughly 250,000 when patients with comorbidities such as type 2 diabetes are included. Most patients have not been diagnosed and would need genetic testing, she said. Vertex would likely launch inaxaplin with a companion diagnostic if the drug is approved.

Pain and Other Pipeline Updates

Results from two phase 3 studies of JOURNAVX in diabetic peripheral neuropathy are expected in the first half of 2027. Both compare the treatment with placebo, and one also includes pregabalin as a comparator. Lisa said managing the placebo effect is an important factor in the trials.

For acute pain, Lisa said Vertex is on track to more than triple JOURNAVX prescriptions in 2026 compared with 2025. Revenue conversion has been slower than some investors expected, however, partly because of reimbursement and prescription logistics. The company plans to keep its free-drug patient support program in place until the middle of 2027 before gradually phasing it out, she said.

Vertex also expects phase 2 proof-of-concept results in myotonic dystrophy type 1 before year-end. A separate pain program targeting NaV1.7 remains in late preclinical development, with the company hoping to enter clinical testing in 2027, Lisa said.

For atumelnant, a treatment being studied in congenital adrenal hyperplasia, Vertex expects to complete enrollment in its adult phase 3 study in the first quarter of 2027. Data disclosure is expected in late 2027 or early 2028, said Manisha Pai, executive director of investor relations.

Pai said Vertex has not set a timeline for data from an ongoing pediatric phase 2 study. In the adult phase 2 open-label extension, the company has not seen liver issues, she said; Vertex expects to share data from that extension at a medical meeting in 2027.

About Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex's CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?

Before you consider Vertex Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.

While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines